PBAC's latest decision on Fruquintinib: Recommended with restriction (2024). Considered for Treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with or are not considered candidates for fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and an anti-EGFR therapy.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2024
Submissions
1
2024 → 2024
Eligible population
Adult patients with metastatic colorectal cancer who have been previously treated with or are not considered candidates for fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and an anti-EGFR therapy, with WHO performance status of 1 or less.
Therapy area
Oncology
Line of therapy
Later-line
Evidence base
RCT
Primary endpoint
OS
Key trials
FRESCO 1, FRESCO 2, SUNLIGHT
Comparator
trifluridine/tipiracil (TRI/TIP)
Economic model
Cost-minimisation
Eligible patients/year
800
ICER note
Cost-minimisation analysis approach; no ICER calculated by design.